Regenerative Medicine Market

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

Report Code: BT 4419 Sep, 2020, by marketsandmarkets.com

[165 Pages Report]The global regenerative medicine market is expected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products.

Regenerative Medicine Market

To know about the assumptions considered for the study, Request for Free Sample Report

OVID-19 Impact on Global Regenerative medicine market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak will impact the regenerative medicine market in the initial phase of the forecast period. Due to nationwide lockdowns, denied wound care services, cancelled or postponed elective surgeries, and increasing skin injuries in COVID-19 medical care providers, the regenerative medicine market is expected to register a certain decline during the forecast period. However, during the latter half of the forecast period, the demand for regenerative medicine products is expected to rise drastically.

Market Dynamics

Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer

Over the last few decades, the incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe. Diabetes and obesity can result in the increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, which require treatments and incur exorbitant medical expenses.

Opportunity: Implementation of the 21st Century Cures Act

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation and covers various provisions that may impact the development and approval of several products in the coming years.

Restraint: High cost cell and gene therapies

Cell and gene therapies represent a significant scientific and medical advancement for patients suffering from terminal illnesses and serious disorders. These therapies are helping to transform how diseases are treated and potentially cured. Furthermore, such therapies will eventually enable doctors and medical professionals to infuse genes/cells via injectable means in order to avoid a series of drugs and multiple surgeries in patients. However, despite the fact of these therapies being lifesavers and more effective compared to the traditional treatments, the response in terms of demand for these therapies is less compared to the anticipation. This can be attributed to the high costs of these therapies and difficulty in obtaining reimbursements and coverage for these therapies.

Tissue-engineered products segment accounted for the largest share of the regenerative medicine market, by product, in 2019

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Musculoskeletal segment accounted for largest share in the market, by application, in 2019

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the musculoskeletal disorders segment accounted for the largest market share. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

North America is the largest regional market for regenerative medicine market

The global regenerative medicine market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the regenerative medicine market. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Regenerative Medicine Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the regenerative medicine market (2020- 2025)

Scope of the Report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Product, application, and region

Geographies covered

North America, Europe, Asia Pacific, and Rest of the Wo

Companies covered

3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).

This report categorizes the regenerative medicine market into the following segments and subsegments:

By Product

  • Tissue-engineered Products
  • Cell Therapies
    • Autologous Therapies
    • Allogenic Therapies
  • Gene Therapies
  • Progenitor & Stem Cell Therapies

By Application

  • Musculoskeletal
  • Oncology
  • Wound Care
  • Dental
  • Ocular
  • Other Applications

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia Pacific 
  • Rest of the World

Recent Developments

  • In February 2020, Integra Lifesciences (US) launched AmnioExcel Plus Placental allograft membrane.
  • In November 2019, Stryker Corporation (US) acquired Wright Medical (US) to strengthen its product portfolio.
  • In March 2019, Smith & Nephew (UK) acquired Osiris Therapeutics (US) to strengthen its product portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 24)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
        FIGURE 1 INCLUSIONS & EXCLUSIONS
           1.2.1 MARKETS COVERED
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 REPORT COMPARISON WITH THE MARCH 2019 EDITION
           1.6.1 SUMMARY OF CHANGES
           1.6.2 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA
        FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                 FIGURE 4 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
                 FIGURE 5 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 35)
  FIGURE 7 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
  FIGURE 8 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
  FIGURE 9 REGENERATIVE MEDICINE MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 38)
    4.1 REGENERATIVE MEDICINE MARKET OVERVIEW
        FIGURE 10 GROWING INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
    4.2 CELL THERAPIES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
        FIGURE 11 AUTOLOGOUS CELL THERAPIES TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN THE FORECAST PERIOD
    4.3 REGENERATIVE MEDICINE MARKET SHARE, BY APPLICATION, 2020 VS. 2025
        FIGURE 12 MUSCULOSKELETAL DISORDERS IS THE LARGEST APPLICATION SEGMENT OF THE REGENERATIVE MEDICINE MARKET
    4.4 REGENERATIVE MEDICINE MARKET, BY REGION, 2020−2025
        FIGURE 13 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 41)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 14 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of chronic diseases, genetic disorders, and cancer
                            FIGURE 15 INCIDENCE OF DIABETES, BY REGION, 2015 VS. 2040 (MILLION CASES)
                            TABLE 1 CANCER INCIDENCE AND MORTALITY, BY REGION, 2012–2035
                            TABLE 2 OBESITY-ASSOCIATED DEATH RATE (%), BY COUNTRY, 2017
                    5.2.1.2 Rising investments in regenerative medicine research
                            TABLE 3 TOTAL FUNDING, BY SOURCE TYPE, 2016–2019 (USD MILLION)
                            TABLE 4 FUNDING FROM CORPORATE PARTNERSHIPS, 2018–2019 (USD MILLION)
                            TABLE 5 FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO & FOLLOW-ONS), 2018–2019 (USD MILLION)
                            TABLE 6 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY THE NIH UNDER THE 21ST CENTURY CURES ACT, 2017–2019 (USD BILLION) 46
                            TABLE 7 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH (2017)
                    5.2.1.3 Growing pipeline of regenerative medicine products
                            TABLE 8 NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2016–2018
                            TABLE 9 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, BY CLINICAL PHASE, 2018 VS. 2019
                            TABLE 10 NUMBER OF M&A TRANSACTIONS, 2016–2019 (USD MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 Ethical concerns related to the use of embryonic stem cells in research & development
                    5.2.2.2 High cost of cell and gene therapies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Implementation of the 21st Century Cures Act
                    5.2.3.2 Rising demand for organ transplantations
    5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE REGENERATIVE MEDICINE MARKET

6 REGENERATIVE MEDICINE MARKET, BY PRODUCT (Page No. - 51)
    6.1 INTRODUCTION
        TABLE 11 FUNDING FOR REGENERATIVE MEDICINE PRODUCTS, 2019 (USD BILLION)
        TABLE 12 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, 2018 VS. 2019
        TABLE 13 NEW PRODUCT APPROVALS IN THE REGENERATIVE MEDICINE MARKET, 2018-2020
        TABLE 14 REGENERATIVE MEDICINE MARKET: PRODUCT PIPELINE (2019)
        TABLE 15 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
    6.2 TISSUE-ENGINEERED PRODUCTS
           6.2.1 RISING PREVALENCE OF CHRONIC WOUNDS TO DRIVE THE MARKET GROWTH
                 TABLE 16 EXAMPLES OF COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS
                 TABLE 17 TISSUE-ENGINEERED PRODUCTS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 18 NORTH AMERICA: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 19 EUROPE: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 20 APAC: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.3 CELL THERAPIES
        TABLE 21 COMMERCIALIZED CELL THERAPIES AVAILABLE IN THE MARKET
        TABLE 22 CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 23 CELL THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION)
        TABLE 24 NORTH AMERICA: CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 25 EUROPE: CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 26 APAC: CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.3.1 AUTOLOGOUS THERAPIES
                    6.3.1.1 Autologous therapies segment to register the highest growth in the cell therapies market
                            TABLE 27 EXAMPLES OF COMMERCIALIZED AUTOLOGOUS CELL THERAPIES
                            TABLE 28 AUTOLOGOUS THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 29 NORTH AMERICA: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 30 EUROPE: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 31 APAC: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.3.2 ALLOGENEIC THERAPIES
                    6.3.2.1 Rising incidence of chronic conditions to drive the market growth
                            TABLE 32 EXAMPLES OF COMMERCIALIZED ALLOGENEIC CELL THERAPIES
                            TABLE 33 ALLOGENEIC THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 34 NORTH AMERICA: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 35 EUROPE: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 36 APAC: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.4 GENE THERAPIES
           6.4.1 GROWING NUMBER OF CANCER CASES TO DRIVE MARKET GROWTH
                 TABLE 37 EXAMPLES OF COMMERCIALIZED GENE THERAPIES
                 TABLE 38 GENE THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 39 NORTH AMERICA: GENE THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 40 EUROPE: GENE THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 41 APAC: GENE THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.5 PROGENITOR & STEM CELL THERAPIES
           6.5.1 GROWING PRODUCT PIPELINE TO SUPPORT THE GROWTH OF THIS SEGMENT
                 TABLE 42 EXAMPLES OF COMMERCIALIZED PROGENITOR & STEM CELL THERAPIES
                 TABLE 43 PROGENITOR & STEM CELL THERAPIES MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 44 NORTH AMERICA: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 45 EUROPE: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 46 APAC: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

7 REGENERATIVE MEDICINE MARKET, BY APPLICATION (Page No. - 69)
    7.1 INTRODUCTION
        TABLE 47 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY APPLICATION, 2018 VS. 2019
        TABLE 48 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    7.2 MUSCULOSKELETAL DISORDERS
           7.2.1 INCREASING PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
                 TABLE 49 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 50 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 51 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 52 APAC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
    7.3 ONCOLOGY
           7.3.1 INCREASING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH
                 TABLE 53 NUMBER OF PATIENTS, BY TYPE OF CANCER, 2012–2030
                 TABLE 54 INDICATIVE LIST OF FEW COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR THE TREATMENT OF CANCER
                 TABLE 55 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 56 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 58 APAC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD MILLION)
    7.4 WOUND CARE
           7.4.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE THE GROWTH OF THIS SEGMENT
                 TABLE 59 REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS
                 TABLE 60 REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 61 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 62 EUROPE: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 63 APAC: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018–2025 (USD MILLION)
    7.5 DENTAL
           7.5.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE THE MARKET GROWTH
                 TABLE 64 REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 65 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 66 EUROPE: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 67 APAC: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
    7.6 OCULAR DISORDERS
           7.6.1 RISING PRODUCT APPROVALS TO DRIVE MARKET GROWTH
                 TABLE 68 REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 69 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 70 EUROPE: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 71 APAC: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018–2025 (USD MILLION)
    7.7 OTHER APPLICATIONS
        TABLE 72 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 73 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 74 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 75 APAC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)

8 REGENERATIVE MEDICINE MARKET, BY REGION (Page No. - 86)
    8.1 INTRODUCTION
        TABLE 76 NUMBER OF PLAYERS IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2018 VS. 2019
        TABLE 77 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY REGION (2019)
        TABLE 78 REGENERATIVE MEDICINE MARKET, BY REGION, 2018–2025 (USD MILLION)
    8.2 NORTH AMERICA
        FIGURE 16 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
        TABLE 79 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 80 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 81 NORTH AMERICA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.2.1 US
                    8.2.1.1 Growing product pipeline to drive the market in the US
                            TABLE 83 PRODUCTS ANTICIPATED FOR APPROVALS IN THE US IN 2020
                            TABLE 84 PRODUCTS ANTICIPATED FOR FILINGS IN THE US IN 2020
                            TABLE 85 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 86 US: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 87 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Increasing investments in R&D to drive market growth
                            TABLE 88 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 89 CANADA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 90 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    8.3 EUROPE
        TABLE 91 EUROPE: RESEARCH FUNDING OVERVIEW (2017)
        TABLE 92 PRODUCTS ANTICIPATED FOR APPROVALS IN EUROPE IN 2020
        TABLE 93 PRODUCTS ANTICIPATED FOR FILINGS IN EUROPE IN 2020
        TABLE 94 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 96 EUROPE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 97 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.3.1 UK
                    8.3.1.1 Rising prevalence of chronic conditions to drive market growth in the UK
                            TABLE 98 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 99 UK: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 100 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.3.2 GERMANY
                    8.3.2.1 Rising healthcare expenditure to propel market growth
                            TABLE 101 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 102 GERMANY: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 103 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Rising R&D expenditure, a major growth driver in France
                            TABLE 104 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 105 FRANCE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 106 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.3.4 REST OF EUROPE
                 TABLE 107 ROE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                 TABLE 108 ROE: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 109 ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    8.4 ASIA PACIFIC
        FIGURE 17 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
        TABLE 110 APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 111 APAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 112 APAC: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 113 APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.4.1 JAPAN
                    8.4.1.1 Comparatively lenient regulations and rising geriatric population to drive market growth
                            TABLE 114 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 115 JAPAN: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 116 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.4.2 CHINA
                    8.4.2.1 Favorable investments and government support to drive market growth in China
                            TABLE 117 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 118 CHINA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 119 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.4.3 AUSTRALIA
                    8.4.3.1 Strong research base and availability of funds to drive market growth
                            TABLE 120 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 121 AUSTRALIA: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
           8.4.4 ROAPAC
                 TABLE 123 ROAPAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                 TABLE 124 ROAPAC: CELL THERAPIES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 125 ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    8.5 REST OF THE WORLD
        TABLE 126 ROW: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 127 ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018–2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 115)
    9.1 OVERVIEW
        FIGURE 18 KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET (JANUARY 2017 –AUGUST 2020)
    9.2 CELL THERAPY MARKET SHARE ANALYSIS
        FIGURE 19 CELL THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
    9.3 GENE THERAPY MARKET SHARE ANALYSIS
        FIGURE 20 GENE THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
    9.4 TISSUE ENGINEERING MARKET RANKING
        FIGURE 21 TISSUE ENGINEERING MARKET RANKING, 2019
    9.5 COMPETITIVE SCENARIO
           9.5.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                 TABLE 128 PRODUCT LAUNCHES & REGULATORY APPROVALS (JANUARY 2017–AUGUST 2020)
           9.5.2 COLLABORATIONS
                 TABLE 129 COLLABORATIONS (JANUARY 2017–AUGUST 2020)
           9.5.3 ACQUISITIONS
                 TABLE 130 ACQUISITIONS (JANUARY 2017–AUGUST 2020)
           9.5.4 EXPANSIONS
                 TABLE 131 EXPANSIONS (JANUARY 2017–AUGUST 2020)

10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 119)
     10.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
             10.1.1 VENDOR INCLUSION CRITERIA
             10.1.2 STARS
             10.1.3 EMERGING LEADERS
             10.1.4 PERVASIVE
             10.1.5 PARTICIPANTS
                    FIGURE 22 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
     10.2 COMPANY EVALUATION MATRIX FOR START-UPS (2019)
             10.2.1 PROGRESSIVE COMPANIES
             10.2.2 RESPONSIVE COMPANIES
             10.2.3 STARTING BLOCKS
             10.2.4 DYNAMIC COMPANIES
                    FIGURE 23 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019
     10.3 COMPANY PROFILES
(Business overview, Products offered, Recent developments, MNM view)*
             10.3.1 SMITH & NEPHEW PLC
                    FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2019)
             10.3.2 VERICEL CORPORATION
                    FIGURE 25 VERICEL CORPORATION: COMPANY SNAPSHOT (2019)
             10.3.3 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
                    FIGURE 26 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
             10.3.4 MIMEDX GROUP
                    FIGURE 27 MIMEDX GROUP: COMPANY SNAPSHOT (2019)
             10.3.5 NOVARTIS AG
                    FIGURE 28 NOVARTIS: COMPANY SNAPSHOT (2019)
             10.3.6 STRYKER CORPORATION
                    FIGURE 29 STRYKER CORPORATION: COMPANY SNAPSHOT (2019)
             10.3.7 ORGANOGENESIS INC.
                    FIGURE 30 ORGANOGENESIS: COMPANY SNAPSHOT (2019)
             10.3.8 MEDIPOST CO., LTD.
                    FIGURE 31 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2019)
             10.3.9 3M GROUP
                    FIGURE 32 3M GROUP: COMPANY SNAPSHOT (2019)
             10.3.10 MISONIX
                     FIGURE 33 MISONIX: COMPANY SNAPSHOT (2019)
             10.3.11 ZIMMER BIOMET
                     FIGURE 34 ZIMMER BIOMET: COMPANY SNAPSHOT (2019)
             10.3.12 MEDTRONIC PLC
                     FIGURE 35 MEDTRONIC PLC: COMPANY SNAPSHOT (2019)
             10.3.13 AMGEN, INC.
                     FIGURE 36 AMGEN, INC.: COMPANY SNAPSHOT (2019)
             10.3.14 ALLERGAN
                     FIGURE 37 ALLERGAN: COMPANY SNAPSHOT (2019)
             10.3.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                     FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2019)
             10.3.16 ORTHOCELL LTD.
             10.3.17 TEGO SCIENCE, INC.
             10.3.18 CORESTEM, INC.
             10.3.19 ANTEROGEN CO., LTD.
             10.3.20 BLUEBIRD BIO
             10.3.21 SPARK THERAPEUTICS
             10.3.22 KITE PHARMA
             10.3.23 APAC BIOTECH
             10.3.24 SHENZHEN SIBIONO GENETECH CO., LTD.
             10.3.25 ASPECT BIOSYSTEMS

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 159)
     11.1 INSIGHTS FROM INDUSTRY EXPERTS
     11.2 DISCUSSION GUIDE
     11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.4 AVAILABLE CUSTOMIZATIONS
     11.5 RELATED REPORTS
     11.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the regenerative medicine market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Regenerative Medicine Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the regenerative medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the regenerative medicine market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Regenerative Medicine Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the regenerative medicine market based on product, application, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
  • To strategically analyze micromarketsΉ with respect to individual growth trends, prospects, and contributions to the overall regenerative medicine market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies²
  • To track and analyze competitive developments such as product launches, partnerships, expansions, collaborations, and acquisitions in the regenerative medicine market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

Regenerative medicine market size and growth rate estimates for counties in Rest of Europe, the Rest of Asia Pacific and Rest of the World

Company profiles

  • Additional five company profiles of players operating in the regenerative medicine market
COVID-19

Get in-depth analysis of the COVID-19 impact on the Regenerative Medicine Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Regenerative Medicine Market

Request For Special Pricing
Report Code
BT 4419
Published ON
Sep, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home